AI IntelligenceFeb 6, 2026Secondary Market
Article
300601.SZ (康泰生物)
Kangtai Biological announced the termination of its planned joint venture establishment with AstraZeneca. The JV was originally slated to be set up in Beijing with a planned capital of 3.4 billion yuan. Reasons for the termination were not disclosed.
Data Cube AI EditorialSource: 36Kr
01
Source Brief
Kangtai Biological announced the termination of its planned joint venture establishment with AstraZeneca. The JV was originally slated to be set up in Beijing with a planned capital of 3.4 billion yuan. Reasons for the termination were not disclosed.
02